Background-Retinol-binding protein 4 (RBP4) may play an important role in the origin of insulin resistance and metabolic syndrome. Few prospective data are available on the relationship between RBP4 and coronary heart disease (CHD). Furthermore, previous studies did not distinguish among full-length and truncated forms of RBP4 that might have various biological activities. Methods and Results-We measured plasma levels of full-length and several C-terminally truncated subfractions of RBP4 among 468 women who developed CHD and 472 matched controls in the Nurses' Health Study cohort during 16 years of follow-up (1990-2006). We observed a temporal variation in the association of full-length RBP4 levels with CHD risk (P=0.04 for testing proportional hazard assumption). In the first 8 years of follow-up, after multivariate adjustment for covariates, the odds ratio of CHD risk comparing extreme quartiles of full-length RBP4 levels was 3.56 (95% confidence interval, 1.21-10.51; P trend =0.003), whereas this association was 0.77 (95% confidence interval, 0.38-1.56; P trend =0.44) in the follow-up period of 9 to 16 years. Results were similar for total RBP4 levels (summed levels of all RBP4 isoforms). Levels of the primary truncated isoform, RBP4-L, were not associated with CHD risk in any follow-up period; the odds ratios for extreme quartiles were 1.29 (95% confidence interval, 0.50-3.32) and 1.20 (95% confidence interval, 0.64-2.26) in the first and second 8 years of follow-up, respectively. Conclusions-In this cohort of women, higher circulating full-length and total RBP4 levels were associated with increased risk of CHD in a time-dependent fashion. Additional data are warranted to confirm the present findings.
R etinol-binding protein 4 (RBP4) is a ≈21-kDa protein secreted by adipocytes and hepatocytes. Strong animal experimental data have suggested that RBP4 is causally involved in the origin of cardiometabolic diseases. 1 First, RBP4 expression is inversely regulated by Glut4 expression. Furthermore, the peroxisome proliferator-activated receptor-γ agonist rosiglitazone lowered adipose RBP4 expression, normalized serum RBP4 levels, and reversed insulin resistance. Finally, transgenic overexpression of RBP4 or injection of human RBP4 in normal mice caused insulin resistance, whereas genetic deletion of RBP4 or lowering of circulating RBP4 levels had the opposite effect.
1 Although cross-sectional human studies generated somewhat inconsistent results between RBP4 levels and insulin resistance or diabetes mellitus, [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] recent prospective studies have shown convincing evidence that supports the findings from animal experiments.
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Clinical Perspective on p 1947
Despite the promising evidence for insulin resistance and diabetes mellitus, data on RBP4 levels in relation to cardiovascular disease (CVD) are rare. Nonetheless, positive associations were documented for circulating RBP4 or RBP4 expression levels with established CVD risk factors, including metabolic syndrome, 6, 7, 15 overall/central obesity, [15] [16] [17] [18] dyslipidemia, 3, 5, 6, 11, 15, 18, 19 inflammatory markers, [20] [21] [22] and hypertension. 18, 23 Moreover, RBP4 levels have been positively associated with carotid intima-media thickness 23, 24 and prevalent CVD events. 15, 25, 26 An intervention study conducted among children further demonstrated that fat mass loss after lifestyle intervention resulted in a reduction in RBP4 levels, which was accompanied by decreased systemic inflammation and insulin resistance. 20 Similarly, in a cross-sectional study, an increase in RBP4 levels over 3 years also predicted worsening of insulin resistance and cardiometabolic risk. 27 However, in the only prospective study of incident coronary heart disease (CHD), RBP4 levels were not associated with CHD risk. 28 Heterogeneity in study design, age, race, and other participant characteristics, as well as limitations of the assays used, 18, 29 across previous studies may explain the discordant observations. Another caveat to be considered is that circulating RBP4 molecules exist in full-length and several truncated forms. 18, 30 Although the biology of different forms of RBP4 is unknown, limited evidence suggests that some forms might be more biologically active than others. 18 Because the commonly used ELISA, Western blotting, and nephelometric assays do not distinguish different forms of RBP4, few studies have examined individual forms of RBP4. 18 Furthermore, depending on the affinity of antibodies to various forms of RBP4, these prevalent assays may measure different forms with different affinity, 29 introducing exogenous variability into the measurement of total RBP4 levels.
In the present prospective investigation, we specifically evaluated different forms of circulating RBP4 measured by a novel assay 18, 31 in relation to the development of CHD among women in the Nurses' Health Study (NHS).
Methods
Study Populations
The NHS cohort consists of 121 700 female registered nurses 30 to 55 years of age who were enrolled in 1976. The response rate to study questionnaires was >94% of potential person-time of follow-up. A total of 32 826 NHS participants provided blood samples in 1989 to 1990 via an overnight courier, and a frozen water bottle was included to keep the samples cool during transportation. The majority of these samples (97%) arrived within 26 hours from blood draw. Immediately on arrival, whole-blood samples were then centrifuged and divided into aliquots in cryotubes as plasma, buffy coat, and red blood cells, which were stored in the vapor phase of liquid nitrogen freezers at −130°C or below until assessment of RBP4 levels. In a pilot study among 7 volunteers, we found an intraclass correlation coefficient of 0.97 for total RBP4 levels in 3 split samples from the same participants. The split samples were processed under 3 conditions: immediately after collection, after 24 hours' storage, and after 48 hours' storage in a container cooled by a frozen water bottle. These data suggested that our sample collection conditions had minimal impact on RBP4 levels.
Nested Case-Control Study Design
We prospectively identified and confirmed 468 incident cases of nonfatal myocardial infarction (MI) and fatal CHD from the date of blood draw through June 2006. We used a risk-set sampling scheme to randomly select 1 control for each case from the rest of the population who remained free of CHD events when the case occurred. To control for confounding, we matched cases and controls for age at blood draw (±1 year), smoking status (never, past, and current), fasting status at blood draw (fasting for 10 hours or not), and date of blood draw. Cases and controls were all free of cancer and CVD at blood collection. In the present study, we had sufficient power (>80%) to detect odds ratios (ORs) ≥1.6 comparing extreme quartiles.
The study protocol was approved by the Institutional Review Board of the Brigham and Women's Hospital and the Human Subjects Committee Review Board of the Harvard School of Public Health.
Assessment of CHD
In baseline and all biennial follow-up questionnaires, we inquire about the occurrence of physician-diagnosed CHD events. We request medical records from participants who report having a nonfatal MI. Study physicians who are blinded to the exposure status of participants review all medical records and confirm or refute the self-reports of nonfatal MI using the World Health Organization criteria that require typical symptoms plus either diagnostic ECG findings or elevated cardiac enzyme levels. 32 Deaths are identified by reports from next of kin or postal authorities or by searching the National Death Index. In a validation study, we demonstrated that at least 98% of deaths among the NHS participants were identified with these approaches. 33 Fatal CHD cases are identified if CHD is listed as the cause of death in autopsy reports, hospital records, or death certificates. Fatal CHD cases are then confirmed by a previous report of CHD and if there is no other more apparent or plausible cause of death. CHD cases are considered probable if study participants confirm diagnoses in telephone interviews or through mail but medical records are not obtained. We included both definite (83.5%) and probable (16.5%) nonfatal MI and fatal CHD cases in the present analysis. Unconfirmed CHD deaths were excluded.
Assessment of Plasma Levels of RBP4
Plasma samples from both cases and controls were processed for RBP4 assays at the same time. Because 98% of the blood samples were collected within 15 months (June 1989-September 1990), the storage duration of these samples did not substantially differ among the participants. In addition, because blood collection time and subsequent CHD diagnosis date were entirely unrelated, case-control pairs identified in early follow-up periods had the same sample storage duration as those identified at later follow-up.
To minimize systematic measurement error, samples from each case-control pair were handled identically and analyzed in the same run by the same technicians in a random sequence under identical conditions for all assays. We used a novel quantitative mass spectrometry immunoassay to measure plasma levels of full-length and truncated forms of RBP4. This assay is based on the technique of linear time of flight that uses an internal reference standard to internally normalize the mass spectrometry signals. 18, 31 Briefly, 50 µL of a 1/100 dilution of human plasma was mixed in a 1:1 ratio with 0.5% SDS (vol/vol). Mixed samples were incubated at room temperature for 20 minutes to liberate RBP4 from the endogenous transthyretin. Next, each sample was spiked with 50 µL of a 25-µg/µL solution of β-lactoglobulin, which is used as the internal reference standard. Samples were diluted to 1 mL with HEPES-buffered saline. RBP4 and β-lactoglobulin internal reference standard were co-immuno-affinity purified from samples with mass spectrometry immunoassay tips tailored to specifically retrieve both of these analytes. Mass spectra were generated by matrix-assisted laser desorption/ionization-time of flight and analyzed with Zebra mass spectrometry software (Intrinsic Bioprobes, Inc, Tempe, AZ).
This novel assay can distinguish full-length RBP4 from 3 truncated forms of RBP4, ie, RBP4-L (the most abundant truncated form that lacks a leucine at the C-terminal end), RBP4-LL (lacks 2 C-terminal leucines), and RBP4-RNLL (the least abundant truncated form that lacks arginine, asparagine, and 2 leucines at the C-terminal end). To be comparable with most prior investigations that assayed total RBP4 levels only, we derived total RBP4 levels by adding the levels of full-length RBP4, RBP4-L, RBP4-LL, and RBP4-RNLL. Total RBP4 levels measured by mass spectrometry immunoassay correlate strongly with those determined by Western blotting (r=0.91). 18 Quality-control samples were dispersed throughout each analytic run. Based on the measurements of these control samples, the average intra-assay coefficient of variation was 7.0% for full-length RBP4 and 10.5% for RBP4-L. Because RBP4-LL and RBP4-RNLL were not detectable in most quality-control samples, coefficient of variation data were not available for these 2 markers.
In the present investigation, we used existing data on an array of CVD risk markers, including total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, (HbA 1c ) , and creatinine levels, to explore the interrelationship between RBP4 and these markers, which were associated with RBP4 levels in prior investigations.
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Assessment of Covariates
In NHS questionnaires, we inquire about medical history, major lifestyle practices, and other risk factors for CHD, including body weight, cigarette smoking, physical activity, family history of MI, menopausal status, and postmenopausal hormone use. Information about history of hypertension, hypercholesterolemia, and diabetes mellitus was based on self-report. Body mass index as weight in kilograms divided by the square of height in meters was calculated to assess overall adiposity. Diet has been assessed with validated semiquantitative food frequency questionnaires every 2 to 4 years since 1980. We used covariates assessed with the 1990 questionnaire in the analysis to control for confounding. We calculated and used cumulative averages of dietary variables through 1990 to represent long-term diet. We derived the estimated glomerular filtration rate (eGFR) using the following equation: eGFR=186×creatinine (mg/dL) −1.154 ×age (years) −0.203 ×0.742. 34 
Statistical Methods
To explore the interrelationship among individual RBP4 forms and the correlations between RBP4 levels and other CVD risk factors, we calculated Spearman partial correlation coefficients among controls and adjusted for age at blood draw; body mass index; fasting status; smoking status; postmenopausal status; hormone use; physical activity; alcohol use; family history of heart disease; intakes of trans fat, polyunsaturated fat, and whole grains; use of aspirin; and eGFR.
We categorized the study population into quartiles according to the distribution of RBP4 levels among controls and used the lowest quartile as the reference group. Conditional logistic regression was used to estimate the OR of CHD by RBP4 quartiles. In nested case-control studies, ORs derived from conditional logistic regression models are unbiased estimates of hazard ratios or relative risks. 35 In the multivariate analysis, we controlled for the aforementioned covariates and history of hypercholesterolemia, diabetes mellitus, or hypertension. P values for linear trend were calculated by entering an ordinal score based on the median value in each quartile of RBP4 levels into the multivariate models. Because the validity of estimates from conditional logistic regression analysis depends on the assumption of proportional hazard, 35 we evaluated this assumption by testing the significance of interaction terms between RBP4 levels and length of follow-up. We used likelihood ratio tests to assess the significance of these interaction terms. In addition, we used restricted cubic spline regressions with 3 knots to model the dose-response relationship between RBP4 levels and risk of CHD. 36 In this analysis, we excluded participants with the lowest and highest 5% of RBP4 levels to minimize the potential impact of outliers. Tests for nonlinearity were based on the likelihood ratio test, comparing the model with only the linear term and the model with the linear and cubic spline terms.
All P values were 2 sided, and 95% confidence intervals (95% CIs) were calculated for ORs. Data were analyzed with the Statistical Analysis Systems software package, version 9.2 (SAS Institute, Inc, Cary, NC). Table 1 shows the characteristics of CHD cases and controls at blood collection in 1989 to 1990. Because of the matching design, cases and controls were similar for age and smoking status. Otherwise, as expected, cases had higher levels of CVD risk factors than controls. For example, cases had a higher body mass index; drank less alcohol; were more likely to have a history of hypertension, diabetes mellitus, and other chronic conditions; and were more likely to have a family history of MI than controls. The distribution of blood lipids, high-sensitivity C-reactive protein, adiponectin, and HbA 1c between cases and controls was also consistent with their higher-risk status. In both cases and controls, fulllength RBP4 was the most abundant form and accounted for >69.5% of total RBP4. RBP4-L accounted for the vast majority (95.4%) of total truncated forms of RBP4. For the 2 minor forms of truncated RBP4, only 20.4% of the participants had detectable RBP4-LL, and only 1.8% had detectable RBP4-RNLL. Although cases had higher levels of full-length and truncated forms of RBP4 than controls, the differences did not reach significance level. Cases and controls also had similar eGFR levels. In controls, who represented the source population for cases, different RBP4 isoforms were significantly correlated with each other (Table I in (Table 2 ). In contrast, RBP4-L levels correlated positively with total cholesterol levels and fasting triacylglycerol and inversely with eGFR, although the strength of correlations was modest. The same correlation pattern was found for total RBP4 levels. RBP4 levels were not correlated with body mass index or waist circumference (data not shown).
Results
To evaluate the proportional hazard assumption, we first examined the temporality of associations between RBP4 levels and CHD risk over the total follow-up period of 16 years. We found evidence suggesting that the proportional hazard assumption was likely violated ( Figure 1A-1C) ; full-length RBP4 levels were associated with higher CHD risk during the first 8 years of follow-up, whereas this association was gradually attenuated during longer follow-up. A similar pattern was found for total RBP4 levels. In contrast, RBP4-L levels were not associated with CHD risk in any of these follow-up periods. When we formally tested the proportional hazard assumption, the P for interaction was 0.04 for the follow-up period (first versus second 8 years of follow-up) with full-length RBP4 quartiles. Because of this violation of the proportional hazard assumption, we focused on the associations for the first 8 years of follow-up (Table 3) , when the test for proportional hazard assumption was not significant (P interaction =0.31).
Characteristics of case-control pairs selected during 0 to 8 and 9 to 16 years of follow-up are shown in Table II in the online-only Data Supplement. Cases occurring during the first 8 years of follow-up had significantly higher baseline levels of full-length and total RBP4 levels than controls. When examined as quartiles (Table 3) , women in the highest RBP4 quartile had an OR of 3.56 (95% CI, 1.21-10.51) compared with those in the lowest quartile after controlling for CHD risk factors that might act as confounders. Additional adjustment for blood lipids, high-sensitivity C-reactive protein, adiponectin, and HbA 1c further strengthened the associations (model 3). In a series of models, we adjusted for all covariates individually to demonstrate the confounding pattern (Table III in the online-only Data Supplement). Adjustment for diet, use of aspirin, eGFR, physical activity, and history of hypertension and high cholesterol attenuated the association, whereas other covariates confounded the association in the opposite direction with various strengths. RBP4-L levels were not associated with CHD risk in any of these models. Associations for total RBP4 and full-length RBP4 were similar, although in each model, the ORs were stronger for total RBP4 than for fulllength RBP4. In contrast to the results in the first 8 years of follow-up, none of the RBP4 forms was associated with CHD risk in the second 8 years of follow-up (Table 4) .
The dose-response relationship between full-length and total RBP4 levels and CHD risk during the first 8 years of ); menopausal status (yes, no); hormone use (current user, past user, and nonuser); physical activity (MET-h/wk); alcohol use (g/d); parental history of myocardial infarction <65 years of age (yes, no); use of aspirin (yes, no); glomerular filtration rate; intakes of whole grains, trans fat, and polyunsaturated fat (in tertiles); and history of hypercholesterolemia, diabetes mellitus, or hypertension (yes, no).
‡Based on model 2, model 3 was further adjusted for total cholesterol (mg/dL), triacylglycerol (mg/dL), high-sensitivity C-reactive protein (mg/L), hemoglobin A 1c (%), and total adiponectin (μg/mL). follow-up is presented in Figure 2A and 2B. We detected a significant linear association for both full-length RBP4 and total RBP4 levels with CHD; the P for linearity was 0.004 for full-length RBP4 and 0.01 for total RBP4, whereas the P for curvature was ≥0.61 for these 2 markers. We further estimated that the OR was 2.01 (95% CI, 1.33-3.04) per standard deviation change in log-transformed full-length RBP4. This association was 1.65 (95% CI, 1.12-2.42) for total RBP4 levels. When we included the extreme RBP4 values (top and bottom 5%) in this analysis, we observed similar dose-response relationships (Figure in the online-only Data Supplement).
We performed several sensitivity analyses to examine the robustness of the associations during the first 8 years of follow-up. Among participants who were free of diabetes mellitus at baseline, full-length RBP4 levels were associated with higher CHD risk; the OR was 3.41 (95% CI, 1.09-10.66; P trend =0.006) comparing extreme quartiles, and this association was 2.10 (95% CI, 0.74-5.99; P trend =0.09) for RBP4-L levels and 3.84 (95% CI, 1.27-11.57; P trend =0.004) for total RBP4. When we restricted the analysis to participants with eGFR levels ≥60 mL/min, we also observed similar associations: The OR was 3.25 (95% CI, 1.03-10.29; P trend =0.02) for full-length RBP4, 1.21 (95% CI, 0.44-3.33; P trend =0.51) for RBP4-L, and 3.89 (95% CI, 1.23-12.33; P trend =0.02) for total RBP4. Finally, when we repeated our analysis using definite CHD cases only, the associations did not change materially. The ORs comparing extreme quartiles of full-length RBP4 levels were 3.04 (95% CI, 1.00-9.20; P trend =0.01) in the first 8 years of follow-up and 0.82 (95% CI, 0.40-1.70; P trend =0.69) in the second 8 years of follow-up.
Discussion
In this prospective case-control study, full-length and total RBP4 levels were associated with CHD risk in a time-dependent manner in that these markers were strongly associated with a monotonically increased risk of CHD during the first 8 years of follow-up but associations were attenuated during longer follow-up. RBP4-L, the major truncated form of RBP4, was not associated with CHD risk in this population. These associations were largely independent of established cardiovascular risk factors, including lifestyle practices, diet, medical history, and CVD risk markers.
Few prospective investigations have examined RBP4 levels and risk of incident CHD. In the only prior prospective investigation conducted among ≈3000 men and women living in the United Kingdom, total serum RBP4 levels measured with a particle-enhanced immunonephelometry assay were not associated with incident CHD after controlling for other CVD risk factors. 28 This study was similar to ours in study design and participant age and race. Therefore, the inconsistency between these 2 studies may be attributable to other factors such as the different methodology for measuring RBP4 levels.
Use of a novel mass spectrometry immunoassay to separate different isoforms of RBP4 is a strength of the present study. CHD indicates coronary heart disease; CI, confidence interval; and RBP4, retinol-binding protein 4. *Model 1 was adjusted for the matching factors: age at blood draw, smoking status (never, past, current), fasting status (yes, no), and time of blood draw. †Based on model 1, model 2 was further adjusted for body mass index (kg/m 2 ); menopausal status (yes, no); hormone use (current user, past user, and nonuser); physical activity (MET-h/wk); alcohol use (g/d); parental history of myocardial infarction <65 years of age (yes, no); use of aspirin (yes, no); glomerular filtration rate; intakes of whole grains, trans fat, and polyunsaturated fat (in tertiles); and history of hypercholesterolemia, diabetes mellitus, or hypertension (yes, no).
‡Based on model 2, model 3 was further adjusted for total cholesterol (mg/dL), triacylglycerol (mg/dL), high-sensitivity C-reactive protein (mg/L), hemoglobin A 1c (%), and total adiponectin (μg/mL).
by guest on May 1, 2017 http://circ.ahajournals.org/ Although the biology of different isoforms of RBP4 is largely unknown, the present study suggests that full-length RBP4 may be the most biologically active isoform of RBP4 because this marker, but not the truncated isoforms, was strongly associated with CHD risk. On the other hand, levels of RBP4-L, but not full-length RBP4, were significantly correlated with fasting triacylglycerol and total cholesterol levels in the present study, although the difference between the correlations was rather small. In this study, we cannot examine whether insulin resistance may explain the associations for full-length RBP4 because we do not have direct measurements of insulin resistance such as the homeostasis model of assessment indexes or euglycemic clamp data. Moreover, it is not surprising that full-length RBP4 levels were not associated with HbA 1c because previous studies showed that serum RBP4 was linked much more tightly to insulin resistance than to glycemia per se. 4 The 2 minor truncated forms of RBP4, RBP4-LL and RBP4-RNLL, were not detectable for most participants in our study or in a previous investigation, 18 making it difficult to evaluate these forms in relation to disease outcomes in human studies. Nonetheless, more data are needed to elucidate the biology of individual isoforms of RBP4 with respect to CVD origin. It is of particular interest to understand whether the expression levels of individual isoforms of RBP4 are different in adipose tissue and liver and whether such a difference may explain the association between these isoforms and disease outcomes in humans.
In addition to the use of a novel assay, our investigation has several other strengths, including high follow-up rates, well-phenotyped clinical CHD, adjustment for a wide array of covariates, and rigorous quality control of laboratory procedures. Meanwhile, a few limitations of the present analysis are worth discussing. First, the study participants are all female nurses, and most are white. Therefore, it is Odds ratio of coronary heart disease (95% confidence intervals [CIs] ) by levels of fulllength and total plasma retinol-binding protein 4 (RBP4). Study participants with the lowest and highest 5% of RBP4 levels were excluded to minimize the potential impact of outliers. Multivariate conditional logistic regression models were adjusted for the same set of covariates for model 2 in Table 3 . Solid lines are odds ratios; dashed lines, 95% CIs. The dotted vertical lines represent the cut-off points for making quartiles listed in Table 3 . A, Full-length RBP4. B, total RBP4.
by guest on May 1, 2017 http://circ.ahajournals.org/ Downloaded from unknown whether the results can be generalized to other races or populations with different characteristics. In addition, because of possible sex differences in RBP4 metabolism, 37 whether these results pertain to men is unclear. Second, although we controlled for many established CVD risk factors to reduce confounding, we cannot exclude the possibility of residual confounding. Of note, blood RBP4 levels increase among patients with renal insufficiency because of impaired renal clearance of RBP4. 38, 39 Therefore, diseases that impair renal function such as renal failure and diabetes mellitus may confound the associations for RBP4, especially for the truncated isoforms. 40 However, in the present analysis, no participants were diagnosed with renal failure at baseline. When we excluded prevalent diabetes mellitus cases or restricted analyses to those with normal eGFR, we observed similar associations. Moreover, we controlled for eGFR and HbA 1c levels in the analysis to minimize confounding by these conditions. Third, we measured only baseline RBP4 levels. A 1-time measurement may not necessarily represent long-term average levels of RBP4 because RBP4 levels may change as a consequence of weight loss and possibly other factors. 7, 41 This may potentially explain the observed attenuated association between RBP4 levels and CHD risk during the extended follow-up (>8 years). On the other hand, our pilot study for examining within-person stability of RBP4 levels demonstrated that the intraclass correlation coefficient was 0.80 for total RBP4 levels among 2 to 3 blood samples collected from 45 volunteers during a time frame of 1 to 3 years, indicating that a single measurement of RBP4 level may reasonably represent average RBP4 levels over several years (unpublished data). Fourth, RBP4 molecules might possibly degrade to some extent after long-term storage, although this scenario was unlikely because the samples were stored at such a low temperature (−130°C or below). In addition, such degradation, if any, should influence all samples (both cases and controls) nondifferentially and therefore would likely attenuate true associations. Fifth, levels of transthyretin, a molecule that binds RBP4 and prevents its renal clearance, 42 are not available. Therefore, we are unable to examine the role of transthyretin in the association between RBP4 and CHD. Previous studies have suggested positive associations between transthyretin and CVD risk factors, 43 and transthyretin was modestly elevated in insulin-resistant people. 5 More studies are warranted to explore the role of transthyretin in the associations of RBP4. Finally, we cannot entirely exclude the possibility that the time-dependent associations are attributable to chance; more data are needed to elucidate the temporality of the association between RBP4 levels and CHD risk.
Conclusions
We found that full-length RBP4 levels were associated with a 3-fold increased risk of incident CHD in women, whereas truncated isoforms of RBP4 were not associated with CHD risk in this population. Although we have found evidence that RBP4 may play a role in the development of CHD and that different isoforms of RBP4 may not have the same biological effects, further studies are warranted to confirm these novel findings.
CLINICAL PeRSPeCTIve
Evidence from animal experiments has clearly demonstrated a causal role of retinol-binding protein 4 (RBP4), a cytokine secreted by adipocytes and hepatocytes, in the origin of insulin resistance. Although emerging data from human studies also suggest a link between this molecule and glucose intolerance, as well as many other cardiovascular risk factors, prospective studies examining RBP4 levels in relation to coronary heart disease (CHD) are few. With recent advances in the methodology of measuring RBP4 levels, investigators are now able to distinguish different forms of RBP4 that may have various biological activities and thus are likely associated with CHD risk differentially. Using data from the well-characterized female Nurses' Health Study, we measured full-length and truncated forms of RBP4 and prospectively evaluated their associations with CHD risk in a nested case-control study. We found an interesting temporal pattern in the associations under investigation. After multivariate adjustment of established CHD risk factors, levels of the full-length RBP4 were significantly associated with elevated risk of CHD during the first 8 years of follow-up, whereas this association was gradually attenuated thereafter. The truncated forms of RBP4 were not associated with CHD in this investigation, and no temporal pattern was observed for these forms. These novel data support the notion that the full-length RBP4 is the most biologically active form predicting future CHD events, although future studies are warranted to corroborate the temporal pattern of this association documented in the present study. *Spearman correlation coefficients were adjusted for age at blood draw (yr), body mass index (kg/m 2 ), fasting status (yes, no), smoking status (current smoker, past smoker, non-smoker), postmenopausal status (yes, no), hormone use (current user, past user, and non-user), physical activity (MET-hrs/week), alcohol use (g/day), family history of heart disease (yes, no), intakes of trans fat, polyunsaturated fat, and whole grains (all in tertiles), and use of aspirin. Glomerular filtration rate was further adjusted except when calculating the correlation coefficient for this variable.
†P<0 
